Orion Portfolio Solutions LLC Sells 17,393 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Orion Portfolio Solutions LLC lowered its holdings in shares of AtriCure, Inc. (NASDAQ:ATRCFree Report) by 24.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 53,761 shares of the medical device company’s stock after selling 17,393 shares during the period. Orion Portfolio Solutions LLC owned 0.11% of AtriCure worth $1,883,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of ATRC. RiverPark Advisors LLC acquired a new position in shares of AtriCure during the 3rd quarter worth approximately $27,000. Allspring Global Investments Holdings LLC lifted its stake in shares of AtriCure by 31.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,074 shares of the medical device company’s stock worth $91,000 after buying an additional 497 shares during the last quarter. Quest Partners LLC acquired a new position in AtriCure in the 4th quarter valued at about $103,000. Victory Capital Management Inc. grew its stake in AtriCure by 22.9% in the 4th quarter. Victory Capital Management Inc. now owns 6,202 shares of the medical device company’s stock valued at $221,000 after buying an additional 1,155 shares during the last quarter. Finally, Aigen Investment Management LP raised its holdings in AtriCure by 24.0% in the 4th quarter. Aigen Investment Management LP now owns 7,136 shares of the medical device company’s stock valued at $255,000 after acquiring an additional 1,383 shares during the period. Institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ATRC shares. StockNews.com cut AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. Oppenheimer upgraded shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a research note on Tuesday, April 23rd. UBS Group raised their target price on shares of AtriCure from $57.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Stifel Nicolaus cut their price target on AtriCure from $50.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Finally, JPMorgan Chase & Co. lowered their price objective on AtriCure from $42.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and an average price target of $49.78.

View Our Latest Analysis on ATRC

Insider Activity at AtriCure

In other AtriCure news, insider Justin J. Noznesky sold 1,500 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the sale, the insider now owns 74,284 shares of the company’s stock, valued at $2,727,708.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Karl S. Dahlquist sold 1,885 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $32.16, for a total value of $60,621.60. Following the completion of the transaction, the insider now owns 50,954 shares of the company’s stock, valued at $1,638,680.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Justin J. Noznesky sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the completion of the transaction, the insider now owns 74,284 shares of the company’s stock, valued at approximately $2,727,708.48. The disclosure for this sale can be found here. Insiders sold a total of 14,616 shares of company stock valued at $504,932 in the last quarter. Insiders own 3.20% of the company’s stock.

AtriCure Trading Up 3.0 %

Shares of ATRC stock opened at $22.26 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 4.00. AtriCure, Inc. has a fifty-two week low of $20.19 and a fifty-two week high of $59.61. The company has a market cap of $1.06 billion, a PE ratio of -27.82 and a beta of 1.41. The stock’s fifty day moving average price is $24.23 and its two-hundred day moving average price is $31.39.

AtriCure (NASDAQ:ATRCGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $108.90 million during the quarter, compared to analyst estimates of $106.86 million. AtriCure had a negative net margin of 8.98% and a negative return on equity of 7.85%. The business’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period last year, the business earned ($0.23) earnings per share. Equities analysts predict that AtriCure, Inc. will post -0.75 EPS for the current fiscal year.

AtriCure Company Profile

(Free Report)

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

Featured Articles

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.